Literature DB >> 1904628

Selective elimination of HIV-1-infected cells with an interleukin-2 receptor-specific cytotoxin.

R W Finberg1, S M Wahl, J B Allen, G Soman, T B Strom, J R Murphy, J C Nichols.   

Abstract

Infection by human immunodeficiency virus type 1 (HIV-1) is associated with cellular activation and expression of the interleukin-2 (IL-2) receptor. A genetically engineered fusion toxin, DAB486 IL-2, that contains the enzymatic site and translocation domain of diphtheria toxin and the receptor binding domain of IL-2 specifically kills cells that express high-affinity IL-2 receptors. This toxin selectively eliminated the HIV-1-infected cells from mixed cultures of infected and uninfected cells and inhibited production of viral proteins and infectious virus. Thus, cellular activation antigens present a target for early antiviral intervention.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1904628     DOI： 10.1126/science.1904628

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  12 in total

Review 1.  What future for therapeutic prevention of type 1 (insulin-dependent) diabetes mellitus?

Authors:  P Pozzilli; A Signore; D Andreani
Journal:  Diabetologia       Date:  1992-11       Impact factor: 10.122

2.  Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin.

Authors:  M Varughese; A V Teixeira; S Liu; S H Leppla
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

3.  Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissues.

Authors:  S M Wahl; P Worley; W Jin; T B McNeely; S Eisenberg; C Fasching; J M Orenstein; E N Janoff
Journal:  Am J Pathol       Date:  1997-04       Impact factor: 4.307

4.  Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs.

Authors:  Edward A Berger; Ira Pastan
Journal:  PLoS Pathog       Date:  2010-06-10       Impact factor: 6.823

5.  Anti-nerve growth factor Ab abrogates macrophage-mediated HIV-1 infection and depletion of CD4+ T lymphocytes in hu-SCID mice.

Authors:  Enrico Garaci; Stefano Aquaro; Caterina Lapenta; Alessandra Amendola; Massimo Spada; Sonia Covaceuszach; Carlo-Federico Perno; Filippo Belardelli
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-09       Impact factor: 11.205

6.  Combined use of an immunotoxin and cyclosporine to prevent both activated and quiescent peripheral blood T cells from producing type 1 human immunodeficiency virus.

Authors:  K D Bell; O Ramilo; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

7.  Mycobacterium avium complex augments macrophage HIV-1 production and increases CCR5 expression.

Authors:  S M Wahl; T Greenwell-Wild; G Peng; H Hale-Donze; T M Doherty; D Mizel; J M Orenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

8.  Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro.

Authors:  T B McNeely; M Dealy; D J Dripps; J M Orenstein; S P Eisenberg; S M Wahl
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

Review 9.  Interleukin-2 and human immunodeficiency virus infection: pathogenic mechanisms and potential for immunologic enhancement.

Authors:  A Kinter; A S Fauci
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

10.  CD25+ FoxP3+ Memory CD4 T Cells Are Frequent Targets of HIV Infection In Vivo.

Authors:  Mkunde Chachage; Georgios Pollakis; Edmund Osei Kuffour; Kerstin Haase; Asli Bauer; Yuka Nadai; Lilli Podola; Petra Clowes; Matthias Schiemann; Lynette Henkel; Dieter Hoffmann; Sarah Joseph; Sabin Bhuju; Leonard Maboko; Fred Stephen Sarfo; Kirsten Eberhardt; Michael Hoelscher; Torsten Feldt; Elmar Saathoff; Christof Geldmacher
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.